PPT-Daclatasvir + Sofosbuvir + RBV in GT3

with Advanced Liver Disease ALLY3 Study Phase 3 Treatment Naïve and TreatmentExperienced Leroy V et al Hepatology 201663143041 Source Leroy V et al Hepatology 201663143041. + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles. DL, . et al. . N . Engl. J Med. 2015;373:714-25.. Source: . Wyles. . + . Sofosbuvir. in Genotype . 3. ALLY-3 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Nelson DR, . et al. . . Hepatology. 2015;61:1127-35.. Source: . Nelson DR, et al. . ELECTRON (Overview): 6 parts, 22 arms. Phase . 2. Treatment. Naïve and Treatment . Experienced. Source: . Gilead Sciences, . Inc. Sofosbuvir. Summary of ELECTRON Trials Design (1 of 2). Part 1 . - . With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles DL, . et al. . N Engl J Med. 2015;373:714-25.. Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.. (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. Genotype . 2. . or 3 . FUSION. Trial. Phase . 3. *Note: Published . in . NEJM in tandem . with . POSITRON Trial (GT 2,3 Unable to receive PEG). Treatment. . Experienced. Jacobson I, et al. N . Engl. HIV Coinfection & HCV . GT 1,2,3. PHOTON-1 Trial. Phase . 3. Sulkowski. MS, et al. JAMA. 2014;312:353-61.. Treatment. Naïve and Treatment . Experienced. HIV Coinfection. Source: . Sulkowski. MS, et al. JAMA. 2014;312:353-61.. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . VALENCE Trial. Phase . 3. Treatment. Naïve and Treatment . Experienced. Zeuzem. S, et al. . N . Engl. J Med. 2014;370:1993-2001. Source: . Zeuzem. S, et al. N . Engl. J Med. 2014;370:1993-. 2001.. SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment Naïve and Treatment Experienced. Charlton M, al. Gastroenterology. 2015; 149:649-59.. Source: Charlton M, . et al. . Gastroenterology. 2015; 149:649-59.. Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. -. Beclabuvir in GT1 Patients without Cirrhosis. UNITY-1 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Poordad F, . et al. . JAMA 2015;313:1728-35.. Source: . Poordad F, et al. JAMA 2015;313:1728-35..